[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100564943":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":19,"responsibleParty":26,"collaborators":30,"id":34,"slug":35,"hasResults":36,"nctId":37,"briefTitle":38,"officialTitle":39,"acronym":19,"eligibilityCriteria":40,"healthyVolunteers":41,"sex":42,"minAge":43,"maxAge":44,"enrollmentInfo":45,"targetDuration":19,"studyType":48,"phases":49,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":56,"whyStopped":19,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":19},{"fullName":5,"class":6},"Stanford University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Vinpocetine","EXPERIMENTAL","Participants will take increasing, single doses of vinpocetine.",[13],"Drug: Vinpocetine",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Increasing doses of vinpocetine to assess tolerability.",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Jordan Seliger","CONTACT","650-460-9260","jseliger@stanford.edu",{"type":27,"investigatorFullName":28,"investigatorTitle":29,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"PRINCIPAL_INVESTIGATOR","Kimford Jay Meador","Professor of Neurology",[31],{"name":32,"class":33},"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","NIH","100564943","phase-1-dose-escalation-study-of-vinpocetine-in-healthy-volunteers-100564943",false,"NCT06635746","Dose Escalation Study of Vinpocetine in Healthy Volunteers","Phase I, Open Label, Dose-Escalation Study for Maximum Tolerated Vinpocetine Dose in Healthy Volunteers","Inclusion Criteria:\n\n1. Healthy adults 18-40 years old.\n2. Proficient English.\n3. Use of appropriate contraception if woman of childbearing potential.\n\nExclusion Criteria:\n\n1. Major medical disease (e.g., epilepsy, diabetes, heart disease, active cancer, depression).\n2. Those who score \\>18 overall on the BDI-II or \\>0 for item #9 (suicidal thoughts) at screening.\n3. Use of centrally active medications.\n4. History of allergy to vinpocetine.\n5. IQ\\\u003C80.\n6. BMI≥30.\n7. Pregnancy or lactation.",true,"ALL","18 Years","40 Years",{"count":46,"type":47},20,"ESTIMATED","INTERVENTIONAL",[50],"PHASE1","The objective of this study is to determine whether vinpocetine is safe when taken at higher doses.",[53],"Fetal Alcohol Spectrum Disorders",[55,9],"Cognition","NOT_YET_RECRUITING","2024-10-08",{"date":59,"type":60},"2024-10-10","ACTUAL",{"date":62,"type":47},"2025-06-01",{"date":64,"type":47},"2026-06-01",{"name":5,"class":6}]